medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Racial/ethnic differences in pre-pregnancy conditions and adverse maternal outcomes in the nuMoM2b cohort: a population-based cohort study

Short Title: *Pre-Pregnancy Conditions and Adverse Maternal Outcomes*

Meghan E. MEREDITH, BS
H. Milton Stewart School of Industrial and Systems Engineering
Georgia Institute of Technology
755 Ferst Drive, NW Atlanta, GA 30332

Lauren N. STEIMLE*, PhD
H. Milton Stewart School of Industrial and Systems Engineering
Georgia Institute of Technology
755 Ferst Drive, NW Atlanta, GA 30332

Kaitlyn K. STANHOPE, PhD
Department of Gynecology & Obstetrics
Emory University
100 Woodruff Circle, Atlanta, GA 30322 USA

Marissa H. PLATNER, MD
Department of Gynecology & Obstetrics
Emory University
100 Woodruff Circle, Atlanta, GA 30322 USA

Sheree L. BOULET, DrPH
Department of Gynecology & Obstetrics
Emory University
100 Woodruff Circle, Atlanta, GA 30322 USA

* Corresponding author: Lauren N. Steimle, steimle@gatech.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Objective To: (1) determine how pre-existing conditions contribute to racial disparities in adverse maternal outcomes; and (2) incorporate these conditions into models to improve risk prediction for racial minority subgroups.

Design Secondary data analysis of a population-based cohort study.

Setting Academic healthcare institutions in the United States.

Population A cohort of 8,729 women included in the “Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b)".

Methods Poisson regression to estimate adjusted risk ratios, and mediation analysis to evaluate the contribution of multimorbidity to racial/ethnic disparities. Area under the receiver operating characteristic curve (AUC) to evaluate model performance.

Main Outcome Measures Incidence of severe preeclampsia, postpartum readmission, and blood transfusion.

Results In the nuMoM2b cohort (n=8729), accounting for pre-existing conditions attenuated the association between non-Hispanic Black race/ethnicity and risk of severe preeclampsia. Cardiovascular and kidney conditions were associated with risk for severe preeclampsia among all women (aRR, 1.77; CI, 1.61-1.96, and aRR, 1.27; CI, 1.03-1.56 respectively). The mediation analysis results were not statistically significant; however, cardiovascular conditions explained 36.6% of the association between severe preeclampsia and non-Hispanic Black race/ethnicity (p=0.07). The addition of pre-pregnancy conditions increased model performance for the prediction of blood transfusion and severe preeclampsia.

Conclusions Pre-existing conditions may explain some of the association between severe preeclampsia and non-Hispanic Black race/ethnicity. Specific pre-pregnancy conditions were associated with adverse maternal outcomes and the incorporation of comorbidities improved the performance of most risk prediction models.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Funding Research reported in this publication was supported in part by Imagine, Innovate and Impact (I^3) from the Emory School of Medicine, Georgia Tech, and through the Georgia CTSA NIH award (UL1-TR002378) and by the National Science Foundation under grant number DGE-2039655 (Meredith); any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

Keywords Maternal health, Pregnancy Complications, Maternal morbidity, Risk Assessment, Multimorbidity, Comorbidity, Chronic Conditions, Health Disparities

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction

The global maternal mortality rate has stalled after improving between 2000 and 2015.[1] The United States' maternal mortality rate, 23.8 per 100,000 live births, has worsened over the past 20 years,[2,3] and there are staggering racial and ethnic disparities in maternal mortality.[4] In the United States, compared with non-Hispanic white individuals, non-Hispanic Black individuals have 3 to 4 times the risk of dying during childbirth.[5] An estimated 80% of pregnancy-related deaths are considered preventable,[6] and individuals with adverse maternal outcomes have similar preventable factors including provider failure to identify high-risk status and inappropriate management.[7] Two potential targets for addressing pregnancy-related mortality and morbidity are improvements in chronic condition prevention before and during pregnancy and better prediction models for adverse outcomes that may disproportionally affect racial and ethnic minority individuals.

Chronic conditions are associated with a higher risk of adverse maternal outcomes. Deliveries among racial and ethnic minorities, compared with non-Hispanic white individuals, experience significantly higher rates of maternal morbidity and also have a higher prevalence of chronic conditions.[8] Pregnant individuals with multiple co-occurring conditions, or *multimorbidity*, have higher rates of severe maternal morbidity and postpartum readmission.[9] While multimorbidity affects a substantial and likely growing proportion of the global adult population,[10] obstetric research and practice remain largely focused on the impact of single conditions on maternal outcomes,[11] apart from a few studies using administrative data, [12,13] and those creating comorbidity-based risk screening tools.[14–16] When multimorbidity is accounted for, it is typically represented as a binary indication of each condition or an indicator of the number of conditions, but these representations do not consider the types of co-occurring conditions (e.g. hematological and cardiovascular), which may be more relevant for clinical management.

In this study, we investigate the impact of pre-pregnancy conditions and their combined effects on adverse maternal outcomes and whether these effects mediate the

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

relationship between racial disparities and adverse maternal outcomes in a cohort of nulliparous individuals in the United States. A better understanding of which conditions and combinations thereof drive increased maternal risk could inform the development of new clinical care standards for multimorbid pregnant people and potentially improve the ability to risk-stratify pregnant people early in pregnancy.

Methods

Study Population

We conducted a secondary analysis of data from the nuMoM2b prospective cohort study of nulliparous women.[17,18] The study recruited women from hospitals affiliated with eight clinical centers and collected data on each participant over the course of four study visits via in-clinic interviews, self-administered questionnaires, clinical measurements, and chart abstractions. The cohort included 9,289 women who consented to the release of their data.

Data Preparation

For this secondary data analysis, we chose to exclude women who delivered at gestational age < 22 weeks or > 43 weeks and those with terminations and unknown outcomes. We also excluded women with missing race/ethnicity and pre-pregnancy conditions data. To address missing data among confounders, we created 5 imputed datasets using multivariate imputation by chained equations (MICE).[19] Please see Appendix A for more details about the exclusion protocol and Appendix B.1 for more details about the data structure and preparation.

Main Outcome Measures

The primary outcomes of this study were severe preeclampsia, blood transfusion, and postpartum readmission (up to 14 days). These outcomes were selected because they are strongly associated with maternal mortality and morbidity, [20,21] and they have high quality measurements in the nuMoM2b dataset. Appendix B.2 provides details about the definitions and collection of the primary outcomes in the nuMoM2b study.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

We fit prediction models to each of these outcomes individually to preserve the interpretability of model results and compared results across each outcome.

Pre-Pregnancy Conditions

Pre-pregnancy conditions were collected by the nuMoM2b study team at each of the first three visits through an in-person interview with the participant, who indicated the presence of each condition at any time throughout their life. The nuMoM2b study team reconciled this data with chart abstraction to finalize the indication of pre-pregnancy conditions.

The nuMoM2b study team collected 41 pre-pregnancy conditions, and we categorized them into 12 condition types according to the framework of Tang et al.[22] (Appendix Table S3). We grouped the pre-pregnancy conditions based on similarities in treatments, clinical manifestation, or organization in the health care system. For example, we grouped cervical dysplasia, fibroids, and PCOS under the condition type "Gynecological" because they are conditions that affect the function of female reproductive organs and are treated by the same gynecologist specialty branch. The condition types included: Autoimmune, Cardiovascular, Endocrine, Gastrointestinal, Gynecological, Hematologic, Kidney, Lung, Mental, and Neurological. This classification was developed and validated by three of our authors (KS, SB, MP) with extensive medical and specifically obstetric knowledge.

Our analysis considered pairs of co-occurring pre-pregnancy condition types. For example, consider a patient with the following three pre-pregnancy conditions: anemia (hematologic), hypertension (cardiovascular), and migraine headaches (neurological). This patient was indicated to have the following co-occurring condition types: hematologic & cardiovascular, cardiovascular & hematologic, and hematologic & neurological.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Confounders

We adjusted for confounding factors including maternal age, insurance, body mass index (BMI), and sociodemographic information including income and education. Each of these factors were collected during Visit 1, which occurred between gestational age 6 and 14 weeks.

Statistical Analysis

We used Poisson regression models with robust standard errors to analyze the associations between pre-pregnancy condition types, self-reported race/ethnicity, and adverse maternal outcomes with the results reported as crude and adjusted risk ratios (RRs) and 95% confidence intervals (CIs). We used a class-weighting method which gives a higher priority to correctly classifying the subgroup of women who experienced an adverse maternal outcome (see Appendix B.3).

Potential mediators were selected for each adverse maternal outcome in a stepwise process to avoid multicollinearity. Each adverse maternal outcome was regressed by race/ethnicity, confounders, and all potential mediators (all pre-pregnancy condition types and all their combined effects) (hereafter referred to as the “Outcome Model”). Only condition types and combined effects reaching statistical significance (p-value ≤ 0.05) in this model were included in further analysis. Additionally, only combined effects with at least 1% prevalence in the dataset were considered. Next, we used a model-building approach starting with a standard individual-level Poisson model (Model 1, crude), followed by a Poisson model that adjusted for confounders (Model 2, adjusted). We additionally controlled for significant pre-pregnancy condition types (Model 3), and finally, we additionally controlled for significant combined effects between co-occurring pre-pregnancy condition types (Model 4).

Next, we sought to determine if pre-pregnancy condition types and their combined effects contributed to the racial disparities in adverse maternal outcomes using mediation analysis. To analyze mediation, the potential mediator condition types and their combined effects were individually regressed by race/ethnicity and adjusted for

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

confounders ("Mediator Model"). The Outcome and Mediator models were combined to compute the mediation proportion, which estimates the proportion of the risk factor's impact (race/ethnicity) on the outcome that is attributable to the mediator (pre-pregnancy condition type or combined effect).[23] This analysis was conducted for each adverse maternal outcome and results were averaged across the five imputed datasets.

Performance Analysis

Finally, we analyzed the performance of our prediction models (Model 1, Model 2, Model 3, and Model 4) to understand which pre-pregnancy patient characteristics accurately classified adverse maternal outcomes. The performance of each model was evaluated for each racial/ethnic subgroup using the average area under the ROC curve (AUC) across 10-fold cross-validation and across the five imputed datasets.

We used R, version 4.2.1, for all analysis, *caret* in R to train and test our prediction models and *mediate* in R to conduct mediation analysis. We use a p-value threshold of 0.05 for statistical significance.

Results

After exclusions, the final study population included 8729 women (Table 1). Of those, 61.0% (n=5322) identified as non-Hispanic white, 13.1% (n=1145) non-Hispanic Black, 17.0% (n=1487) Hispanic, 3.9% (n = 342) Asian, 4.0% (n=348) multiracial, and 1.0% (n=85) "Other". The non-Hispanic Black subgroup had the youngest average age (23.3 ± 5.3) and the largest average BMI (29.1 ± 8.2). In total, the study population included 157 cases (1.8%) of blood transfusion, 154 cases (1.8%) of postpartum readmission, and 318 cases (3.6%) of severe preeclampsia. The incidence of these adverse maternal outcomes varied by race and ethnicity (Table Appendix S2). The incidence of blood transfusion and severe preeclampsia was highest in non-Hispanic Black women and the incidence of all adverse maternal outcomes was lowest in Asian women.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The most common pre-pregnancy conditions were mental health conditions (14.4%, n=1261), hematologic conditions (13.8%, n=1206), neurological conditions (13.0%, n=1136), and lung conditions (12.5%, n=1091) (Table Appendix S4). Non-Hispanic Black women experienced the highest rates of lung and hematologic conditions, Hispanic women experienced the highest rates of kidney conditions, and multiracial women experienced the highest rates of cardiovascular conditions. Non-Hispanic white women experienced the highest rates of neurological, gastrointestinal, and mental health conditions.

Of all women, 22.8% (n=1989) had co-occurring pre-pregnancy conditions, i.e., 2 or more conditions. Non-Hispanic white women had the highest rates of co-occurring pre-pregnancy conditions (24.9%, n=1327), followed by multiracial women (22.7%, n=79), and Non-Hispanic Black women (20.0%, n=229). The most common co-occurring pre-pregnancy conditions were Mental & Neurological (3.7%, n=322), Lung & Neurological (2.8%, n=248), and Hematologic & Lung (2.5%, n=216) (Table Appendix S5). Among non-Hispanic white women, the most common co-occurring pre-pregnancy conditions were Mental & Neurological (4.7%, n=248), Lung & Neurological (2.9%, n=153), and Hematologic & Lung (2.1%, n=111). Among non-Hispanic Black women, the most common co-occurring pre-pregnancy conditions were Hematologic & Lung (4.4%, n=50) and Cardiovascular & Hematologic (3.4%, n=39).

Compared with non-Hispanic white women, the unadjusted risk of blood transfusion and severe preeclampsia was higher in non-Hispanic Black women. Statistical adjustment for age, sociodemographic information, insurance, and BMI eliminated the elevated risk of blood transfusion in non-Hispanic Black and Hispanic women and eliminated the elevated risk of severe preeclampsia for multiracial women. Statistical adjustment attenuated but did not eliminate the elevated risk of severe preeclampsia in non-Hispanic Black women. The adjusted relative risk (aRR) of severe preeclampsia was higher in non-Hispanic Black (aRR, 1.22; CI, 1.06-1.41) compared to non-Hispanic white women (Table 4).

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

After adjusting for confounders, we controlled for pre-pregnancy condition types (Model 3) and their combined effects (Model 4). Controlling for pre-pregnancy condition types for the outcome of severe preeclampsia attenuated the risk of severe preeclampsia in non-Hispanic Black women (aRR 1.15, CI, 0.99-1.34) (Table 6).

Pre-pregnancy condition types were associated with adverse maternal outcomes (see Tables 2-4). Autoimmune conditions significantly increased the risk for blood transfusion (aRR, 1.36; CI, 1.04-1.78) and postpartum readmission (aRR, 1.55; CI, 1.22-1.97). Hematologic conditions were associated with a significantly increased risk for blood transfusion (aRR, 1.42; CI, 1.23-1.64). Cardiovascular and kidney conditions were associated with a significantly increased risk for severe preeclampsia (aRR, 1.77; CI, 1.61-1.96, and aRR, 1.27; CI, 1.03-1.56 respectively). Accounting for combined effects did not significantly impact effect estimates.

Mediation analysis was conducted on all statistically significant condition types and combined effects for each adverse maternal outcome. There were no significant results at p-value < 0.05; however, cardiovascular conditions accounted for 36.6% of the association between non-Hispanic Black race/ethnicity and severe preeclampsia at p-value 0.07.

Finally, we compared the performance metrics, specifically the area under the receiver operating characteristics curve (AUC), of models with different feature sets to determine the value of different maternal characteristics in predicting the risk of experiencing each of the adverse maternal outcomes (Table Appendix S6). We found gains in overall AUC with the addition of condition types for the prediction of blood transfusion and severe preeclampsia (AUC, 0.55 to 0.59, 0.61 to 0.65, respectively). We computed AUC for each racial and ethnic subgroup to understand how the models performed across the subgroups. AUC varies significantly by race for each adverse maternal outcome. Model 3, which includes race, confounders, and condition types as features, has an AUC range of 0.50-0.67 for blood transfusion, 0.45-0.63 for postpartum readmission, and

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

0.49-0.70 for severe preeclampsia. The largest improvement in AUC from adding condition was in predicting blood transfusion in Multiracial women, from 0.49 to 0.67.

Discussion

Main Findings

Our findings suggest accounting for pre-pregnancy condition types explained some of the association between non-Hispanic Black race/ethnicity and severe preeclampsia. We found that including pre-pregnancy condition types improved diagnostic ability (AUC) in predictive models for blood transfusion and severe preeclampsia, both for the overall cohort and for most individual racial and ethnic groups. These results highlight the potential for risk prediction using pre-pregnancy conditions in a diverse, but low-risk population.

Consistent with previous studies,[5,8,24–26] we found that identification as a minority race was associated with a higher risk of adverse maternal outcomes among a cohort of nulliparous individuals. Adding to some studies that have examined the impact of specific co-occurring condition combined effects,[27,28] our study focused on exploring all potential pre-pregnancy condition type combined effects to understand their association with adverse maternal outcomes (specifically severe preeclampsia, postpartum readmission, and blood transfusion) and quantified the value of including combined effects in predictive models. No pre-pregnancy condition combined effects were significantly associated with adverse maternal outcomes.

We also quantified the association between individual pre-pregnancy condition type and adverse maternal outcomes. Each adverse maternal outcome was associated with different pre-pregnancy condition types, except the autoimmune condition type, which was associated with increased risk for both blood transfusion and postpartum readmission. It is well known that pregnancy is associated with changes in the maternal immune system, and specifically the postpartum period is associated with autoimmune disease flares.[29]

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Our work adds to previous studies on the use of prediction models to predict various adverse outcomes, which have ranged from using symptoms and signs,[14,16] laboratory tests and biomarkers,[30,31] and demographics and medical history.[32,33] With the inclusion of pre-pregnancy condition types, our model yields an AUC of 0.65 for predicting severe preeclampsia, which is comparable to the AUC of previously published obstetric comorbidity indices predicting SMM, which included severe preeclampsia (Bateman, et al.[15]: AUC, 0.65 and Easter, et al.[14] : AUC, 0.70 as reported by Leonard et al.[34]). The prediction models for blood transfusion and severe preeclampsia improved with the addition of pre-pregnancy condition types; however, the model for postpartum readmission did not improve.

Interpretation

Understanding the potential reasons for adverse maternal outcomes is an important pathway to understanding and reducing racial and ethnic disparities and high rates of maternal morbidity and mortality.

Our findings suggest that the presence of pre-pregnancy conditions and confounders may explain some of the observed association between non-Hispanic Black race/ethnicity and severe preeclampsia. In a prior study, Black race was associated with increased odds of pregnancy-induced hypertension after adjustment for preexisting conditions and demographic factors.[35] However, our study adjusts for a different set of preexisting conditions. The prevention and management of these pre-existing conditions, specifically cardiovascular conditions, before, during, and between pregnancies could be an important consideration to decrease racial and ethnic disparities in adverse maternal outcomes. Although the nuMoM2b cohort study collected data on a wide range of pre-pregnancy conditions, we could not explain a large proportion of the disparities in maternal morbidity in this cohort. Future work may benefit from the inclusion of additional data such as the severity and management of morbidity and multimorbidity during the preconception, interconception, and postpartum periods to determine whether differential management reduces the observed disparities.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Our work suggests that information about pre-pregnancy conditions can be useful in improving the ability to risk-stratify individuals. The use of predictive modeling may be useful to further explore the complex relationships of co-occurring conditions. However, more research is necessary to inform best clinical practice for the use of predictive models with a focus on mitigating unintended consequences and preventing the exacerbation of disparities.[36]

Strengths and Limitations

Our study has several strengths. Using a large and comprehensive dataset, we evaluated the association between race and ethnicity, pre-pregnancy conditions, and adverse maternal outcomes in a cohort of nulliparous women in the United States. This dataset contains thoroughly collected data that goes beyond a typical electronic health record including health history and conditions, demographics, and survey questionnaires. Our condition type groupings allowed for larger sample sizes of conditions and more accurate estimates of risk ratios. In addition, the use of feature selection algorithms allowed for the exploration of combined effects to improve model performance for predicting adverse maternal outcomes.

Our study has several important limitations. First, the analysis was limited to the data collected in the nuMoM2b dataset, which only includes nulliparous, predominantly non-Hispanic white women who received regular prenatal care at academic medical centers and began care before 13 weeks and 6 days gestation; thus, our findings may not be generalizable to different birthing populations. Second, the nuMoM2b dataset also does not indicate the severity or long-term treatment status of pre-pregnancy conditions. Third, our dataset only collected data up to 14 days postpartum, although many postpartum readmissions occur after this timespan.[37] Finally, adverse pregnancy outcomes are rare and occur infrequently in the nuMoM2b dataset, particularly as we stratified by racial subgroups and by multimorbidity. A larger sample size may be able to identify more statistically significant associations between pre-pregnancy conditions and maternal outcomes that occur infrequently.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Conclusion

In addition to describing associations between race and ethnicity, pre-pregnancy condition types and their combined effects, and adverse maternal outcomes, our findings indicate that pre-pregnancy conditions may partially explain the association between severe preeclampsia and non-Hispanic Black race/ethnicity. Additionally, data collected at an initial prenatal care visit has utility for predicting the risk of experiencing an adverse maternal outcome. Our study findings have important implications for the preconception care as well as antepartum care of individuals with pre-existing conditions as adequately assessing a patient's risk is essential to providing risk-appropriate and equitable care to prevent adverse maternal outcomes.

Acknowledgments

None.

Disclosure of Interests

The authors report no disclosures of interest.

Contribution to Authorship

All authors were involved in the literature search and in the design of the study. MM and LNS obtained the data and MM performed the data analysis. MM drafted the manuscript with LNS. KS, MP, and SH revised the manuscript for important intellectual content, and all authors were involved in the interpretation of the results. All authors approved the final version to be published.

Details of Ethics Approval

This study was approved by the Georgia Institute of Technology Internal Review Board which deemed it exempt from review.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Funding

Research reported in this publication was supported in part by Imagine, Innovate and Impact (I^3) from the Emory School of Medicine, Georgia Tech, and through the Georgia CTSA NIH award (UL1-TR002378) and by the National Science Foundation under grant number DGE-2039655 (Meredith); any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. *Trends in Maternal Mortality 2000 to 2020, Estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division*.; 2023.
2. Pregnancy Mortality Surveillance System | Maternal and Infant Health | CDC. Accessed May 18, 2022. https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm
3. Hoyert L. D. *Maternal Mortality Rates in the United States, 2019*.; 2021. doi:10.15620/CDC:103855
4. Petersen EE, Davis NL, Goodman D, et al. Racial/Ethnic Disparities in Pregnancy-Related Deaths — United States, 2007–2016. *MMWR Morb Mortal Wkly Rep*. 2019;68(35):762-765. doi:10.15585/MMWR.MM6835A3
5. Liese KL, Mogos M, Abboud S, Decocker K, Koch AR, Geller SE. Racial and Ethnic Disparities in Severe Maternal Morbidity in the United States. *J Racial Ethn Health Disparities*. 2019;6(4):790-798. doi:10.1007/S40615-019-00577-W
6. Trost S, Beauregard J, Chandra G, et al. *Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 US States, 2017-2019*.; 2017.
7. Geller SE, Rosenberg D, Cox S, Brown M, Simonson L, Kilpatrick S. A scoring system identified near-miss maternal morbidity during pregnancy. *J Clin Epidemiol*. 2004;57(7):716-720. doi:10.1016/J.JCLINEPI.2004.01.003
8. Admon LK, Winkelman TNA, Zivin K, Terplan M, Mhyre JM, Dalton VK. Racial and ethnic disparities in the incidence of severe maternal morbidity in the United States, 2012-2015. *Obstetrics and Gynecology*. 2018;132(5):1158-1166. doi:10.1097/AOG.0000000000002937
9. Stanhope KK, Worrell N, Jamieson DJ, Geary FH, Boulet SL. Double, Triple, and Quadruple Jeopardy: Entering Pregnancy With Two or More Multimorbid Diagnoses and Increased Risk of Severe Maternal Morbidity and Postpartum Readmission. *Women's Health Issues*. Published online July 11, 2022. doi:10.1016/J.WHI.2022.06.005
10. *Multimorbidity: A Priority for Global Health Research*.; 2018.
11. Brown HK, McKnight A, Aker A. Association between pre-pregnancy multimorbidity and adverse maternal outcomes: A systematic review. *Journal of multimorbidity and comorbidity*. 2022;12:26335565221096584. doi:10.1177/26335565221096584
12. Admon L, Winkelman T, Moniz M, Davis M, Heisler M, Dalton V. Chronic Disease Prevalence Among Mothers Delivering in the United States, 2004-2013 [38N]. *Obstetrics & Gynecology*. 2017;129(1):S152-S153. doi:10.1097/01.AOG.0000514748.00812.AE
13. Brown CC, Adams CE, George KE, Moore JE. Associations Between Comorbidities and Severe Maternal Morbidity. *Obstetrics and gynecology*. 2020;136(5):892-901. doi:10.1097/AOG.0000000000004057
14. Easter SR, Bateman BT, Sweeney VH, et al. A comorbidity-based screening tool to predict severe maternal morbidity at the time of delivery. *Am J Obstet Gynecol*. 2019;221(3):271.e1-271.e10. doi:10.1016/J.AJOG.2019.06.025
15. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a Comorbidity Index for Use in Obstetric Patients. *Obstetrics and gynecology*. 2013;122(5):957-965. doi:10.1097/AOG.0B013E3182A603BB

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

16. Leonard SA, Kennedy CJ, Carmichael SL, Lyell DJ, Main EK. An Expanded Obstetric Comorbidity Scoring System for Predicting Severe Maternal Morbidity. *Obstetrics and gynecology*. 2020;136(3):440. doi:10.1097/AOG.0000000000004022
17. Goretsky A, Dmitrienko A, Tang I, et al. Data Preparation of the nuMoM2b Dataset. *medRxiv*. Published online August 26, 2021:2021.08.24.21262142. doi:10.1101/2021.08.24.21262142
18. Haas DM, Parker CB, Wing DA, et al. A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b). *Am J Obstet Gynecol*. 2015;212(4):539.e1-539.e24. doi:10.1016/J.AJOG.2015.01.019
19. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. *STATISTICS IN MEDICINE Statist Med*. 1998;18:681-694. doi:10.1002/(SICI)1097-0258(19990330)18:6
20. Matas JL, Mitchell LE, Sharma S V., Louis JM, Salemi JL. Severe maternal morbidity at delivery and postpartum readmission in the United States. *Paediatr Perinat Epidemiol*. 2021;35(6):627-634. doi:10.1111/PPE.12762
21. Dzakpasu S, Deb-Rinker P, Arbour L, et al. Severe maternal morbidity surveillance: Monitoring pregnant women at high risk for prolonged hospitalisation and death. *Paediatr Perinat Epidemiol*. 2020;34(4):427. doi:10.1111/PPE.12574
22. Tang LH, Thygesen LC, Willadsen TG, et al. The association between clusters of chronic conditions and psychological well-being in younger and older people-A cross-sectional, population-based study from the Lolland-Falster Health Study, Denmark. *J Comorb*. 2020;10:2235042X20981185. doi:10.1177/2235042X20981185
23. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. *J Stat Softw*. 2014;59(5):1-38. doi:10.18637/JSS.V059.I05
24. Creanga AA, Bateman BT, Kuklina E v., Callaghan WM. Racial and ethnic disparities in severe maternal morbidity: a multistate analysis, 2008-2010. *Am J Obstet Gynecol*. 2014;210(5):435.e1-435.e8. doi:10.1016/J.AJOG.2013.11.039
25. Leonard SA, Main EK, Scott KA, Profit J, Carmichael SL. Racial and ethnic disparities in severe maternal morbidity prevalence and trends. *Ann Epidemiol*. 2019;33:30-36. doi:10.1016/J.ANNEPIDEM.2019.02.007
26. Grobman WA, Bailit JL, Rice MM, et al. Racial and Ethnic Disparities in Maternal Morbidity and Obstetric Care. *Obstetrics and gynecology*. 2015;125(6):1460. doi:10.1097/AOG.0000000000000735
27. Prophet J, Kelly K, Domingo J, et al. Severe pre-eclampsia among pregnant women with sickle cell disease and HIV. *Pregnancy Hypertens*. 2018;11:87-91. doi:10.1016/J.PREGHY.2018.01.006
28. Czerwinski S, Gollero J, Qiu C, Sorensen TK, Williams MA. Migraine-Asthma Comorbidity and Risk of Hypertensive Disorders of Pregnancy. *J Pregnancy*. 2012;2012. doi:10.1155/2012/858097
29. Borba VV, Zandman-Goddard G, Shoenfeld Y. Exacerbations of autoimmune diseases during pregnancy and postpartum. *Best Pract Res Clin Endocrinol Metab*. 2019;33(6). doi:10.1016/j.beem.2019.101321

medRxiv preprint doi: https://doi.org/10.1101/2022.11.02.22281812; this version posted October 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

30. Schmidt LJ, Rieger O, Neznansky M, et al. A machine-learning–based algorithm improves prediction of preeclampsia-associated adverse outcomes. *Am J Obstet Gynecol*. 2022;227(1):77.e1-77.e30. doi:10.1016/j.ajog.2022.01.026
31. Binder J, Kalafat E, Palmrich P, Pateisky P, Khalil A. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension. *Am J Obstet Gynecol*. 2021;225(3):305.e1-305.e14. doi:10.1016/j.ajog.2021.03.041
32. Sheen JJ, Wright JD, Goffman D, et al. Maternal age and risk for adverse outcomes. *Am J Obstet Gynecol*. 2018;219(4):390.e1-390.e15. doi:10.1016/j.ajog.2018.08.034
33. Erickson EN, Carlson NS. Maternal Morbidity Predicted by an Intersectional Social Determinants of Health Phenotype: A Secondary Analysis of the NuMoM2b Dataset. *Reprod Sci*. Published online 2022. doi:10.1007/S43032-022-00913-2
34. Leonard SA, Kennedy CJ, Carmichael SL, Lyell DJ, Main EK. An Expanded Obstetric Comorbidity Scoring System for Predicting Severe Maternal Morbidity. *Obstetrics and gynecology*. 2020;136(3):440-449. doi:10.1097/AOG.0000000000004022
35. Minhas AS, Ogunwole SM, Vaught AJ, et al. Racial Disparities in Cardiovascular Complications with Pregnancy-Induced Hypertension in the United States. *Hypertension*. 2021;78(2):480-488. doi:10.1161/HYPERTENSIONAHA.121.17104
36. Jean-Francois B, Bailey Lash T, Dagher RK, Green Parker MC, Han SB, Lewis Johnson T. The Potential for Health Information Technology Tools to Reduce Racial Disparities in Maternal Morbidity and Mortality. *J Womens Health*. 2021;30(2):274. doi:10.1089/JWH.2020.8889
37. Declercq ER, Cabral HJ, Cui X, et al. Using Longitudinally Linked Data to Measure Severe Maternal Morbidity. *Obstetrics and gynecology*. 2022;139(2):165-171. doi:10.1097/AOG.0000000000004641

Tables

Table 1: Descriptive Statistics of the nuMoM2b Study Population by race/ethnicity status (before imputing missing data).

BMI, body mass index; Std, standard deviation; HS, high school

	Asian	Hispanic	Multiracial	Non-Hispanic Black	Non-Hispanic White	Other
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Total	342 (3.9%)	1487 (17.0%)	348 (4.0%)	1145 (13.1%)	5322 (61.0%)	85 (1.0%)
Education						
Degree work beyond college	158 (46.2%)	148 (10.0%)	56 (16.1%)	73 (6.4%)	1546 (29.1%)	23 (27.1%)
Completed college	110 (32.2%)	249 (16.8%)	68 (19.5%)	117 (10.2%)	1835 (34.5%)	26 (30.6%)
Some college	31 (9.1%)	443 (29.8%)	87 (25.0%)	336 (29.3%)	795 (14.9%)	12 (14.1%)
Assoc/Tech degree	29 (8.5%)	165 (11.1%)	29 (8.3%)	114 (10.0%)	543 (10.2%)	7 (8.2%)
HS grad or GED	9 (2.6%)	271 (18.2%)	47 (13.5%)	291 (25.4%)	391 (7.4%)	10 (11.8%)
Less than HS grad	4 (1.2%)	206 (13.9%)	61 (17.5%)	214 (18.7%)	212 (4.0%)	6 (7.1%)
Missing	1 (0.3%)	5 (0.3%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
Gravidity						
1	262 (76.6%)	1014 (68.2%)	250 (71.8%)	798 (69.7%)	4116 (77.3%)	63 (74.1%)
2	61 (17.8%)	334 (22.5%)	77 (22.1%)	226 (19.7%)	937 (17.6%)	16 (18.8%)
3 +	19 (5.6%)	139 (9.4%)	21 (6.0%)	121 (10.6%)	269 (5.1%)	6 (7.1%)
Insurance						
Government	34 (9.9%)	825 (55.5%)	147 (42.2%)	692 (60.4%)	764 (14.4%)	25 (29.4%)
Commercial	289 (84.5%)	593 (39.9%)	178 (51.2%)	383 (33.5%)	4406 (82.8%)	54 (63.5%)
Self-pay	86 (25.2%)	144 (9.7%)	47 (13.5%)	71 (6.2%)	1130 (21.2%)	15 (17.7%)
Other	8 (2.3%)	31 (2.1%)	11 (3.2%)	34 (3.0%)	87 (1.6%)	2 (2.4%)
Type of Labor						
Spontaneous, not augmented	69 (20.2%)	270 (18.2%)	67 (19.3%)	168 (14.7%)	953 (17.9%)	15 (17.7%)
Spontaneous, augmented	164 (48.0%)	650 (43.7%)	130 (37.4%)	462 (40.4%)	2181 (41.0%)	32 (37.7%)
Induced	81 (23.7%)	475 (31.9%)	131 (37.6%)	463 (40.4%)	1808 (34.0%)	33 (38.8%)
Cesarean w/o labor or induction	28 (8.2%)	91 (6.1%)	20 (5.8%)	51 (4.5%)	379 (7.1%)	5 (5.9%)
Mode of Delivery						
Vaginal	234 (68.4%)	1046 (70.3%)	264 (75.9%)	788 (68.8%)	3923 (73.7%)	55 (64.7%)
Cesarean						
Planned or scheduled	19 (5.6%)	60 (4.0%)	11 (3.2%)	32 (2.8%)	282 (5.3%)	3 (3.5%)
Unscheduled, non-urgent	49 (14.3%)	188 (12.6%)	44 (12.6%)	181 (15.8%)	702 (13.2%)	21 (24.7%)
Unscheduled, urgent	40 (11.7%)	193 (13.0%)	29 (8.3%)	144 (12.6%)	411 (7.7%)	6 (7.1%)
	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std
Age	31.0 ± 4.7	24.8 ± 5.52	25.0 ± 6.2	23.3 ± 5.3	28.2 ± 5.2	27.9 ± 5.1
BMI	23.3 ± 4.0	26.7 ± 6.0	27.1 ± 6.9	29.1 ± 8.2	25.8 ± 5.8	27.2 ± 6.3
Percent Federal Poverty	590.9 ± 315.8	293.3 ± 263.2	337.4 ± 295.1	208.0 ± 245.0	488.3 ± 299.8	394.3 ± 287.1
Gestational Age at Delivery (weeks)	38.9 ± 1.9	38.8 ± 2.0	38.6 ± 2.1	38.4 ± 2.5	38.9 ± 2.0	38.4 ± 2.6

Table 2: Multilevel Poisson regression with outcome blood transfusion. Bolding indicates statistical significance at 95% confidence. RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects
			RR (95% CI)	
Race				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	**1.29 (1.06 - 1.57)**	1.20 (0.97 - 1.50)	1.19 (0.95 - 1.50)	1.21 (0.96 - 1.52)
Hispanic	**1.28 (1.07 - 1.54)**	1.17 (0.95 - 1.45)	1.19 (0.96 - 1.48)	1.19 (0.96 - 1.48)
Multiracial	0.98 (0.59 - 1.62)	0.94 (0.57 - 1.52)	0.86 (0.54 - 1.36)	0.84 (0.53 - 1.32)
Asian	0.86 (0.47 - 1.59)	0.85 (0.46 - 1.57)	0.88 (0.48 - 1.63)	0.88 (0.48 - 1.63)
Other	1.25 (0.67 - 2.32)	1.21 (0.66 - 2.22)	1.17 (0.66 - 2.06)	1.18 (0.67 - 2.09)
Confounders				
Pre-Pregnancy Conditions				
Cardiovascular			1.11 (0.88 - 1.39)	1.17 (0.92 - 1.48)
Endocrine			1.25 (1.00 - 1.56)	**1.28 (1.02 - 1.60)**
Kidney			1.28 (0.93 - 1.75)	1.27 (0.93 - 1.75)
Hematologic			**1.42 (1.23 - 1.64)**	**1.42 (1.23 - 1.64)**
Autoimmune			**1.36 (1.04 - 1.78)**	**1.36 (1.04 - 1.79)**
Gynecological			0.69 (0.48 - 1.00)	0.73 (0.50 - 1.06)
Combined effects				
Cardiovascular: Endocrine				0.83 (0.38 - 1.83)
Cardiovascular: Gynecological				0.67 (0.22 - 2.02)
Overall AUC	0.56	0.55	0.59	0.59

Table 3: Multilevel Poisson regression with outcome postpartum readmission. Bolding indicates statistical significance at 95% confidence. RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects
			RR (95% CI)	
Race				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	1.17 (0.95 - 1.45)	0.96 (0.75 - 1.21)	0.97 (0.76 - 1.24)	1.01 (0.79 - 1.29)
Hispanic	1.18 (0.98 - 1.43)	1.05 (0.85 - 1.28)	1.08 (0.89 - 1.31)	1.07 (0.88 - 1.30)
Multiracial	1.20 (0.87 - 1.66)	1.10 (0.79 - 1.53)	1.04 (0.73 - 1.48)	1.01 (0.70 - 1.46)
Asian	0.30 (0.05 - 1.61)	0.32 (0.06 - 1.71)	0.29 (0.07 - 1.16)	0.29 (0.08 - 1.05)
Other	1.42 (0.96 - 2.11)	1.36 (0.90 - 2.04)	1.42 (0.94 - 2.16)	1.43 (0.95 - 2.15)
Confounders				
Pre-Pregnancy Conditions				
Cardiovascular			1.20 (1.00 - 1.45)	**1.33 (1.04 - 1.68)**
Lung			1.10 (0.90 - 1.34)	1.26 (0.99 - 1.61)
Endocrine			1.19 (0.97 - 1.45)	**1.33 (1.03 - 1.71)**
Hematologic			1.14 (0.94 - 1.39)	**1.32 (1.02 - 1.71)**
Autoimmune			**1.55 (1.22 - 1.97)**	**1.52 (1.19 - 1.94)**
Neurological			1.09 (0.90 - 1.32)	1.25 (0.99 - 1.58)
Mental			0.97 (0.80 - 1.19)	1.06 (0.85 - 1.31)
Combined effects				
Cardiovascular: Neurological				0.84 (0.57 - 1.25)
Cardiovascular: Endocrine				0.76 (0.52 - 1.11)
Cardiovascular: Hematologic				0.89 (0.61 - 1.32)
Lung: Neurological				0.73 (0.43 - 1.23)
Lung: Endocrine				0.80 (0.48 - 1.33)
Lung: Hematologic				0.84 (0.51 - 1.40)
Neurological: Mental				0.79 (0.50 - 1.27)
Endocrine: Hematologic				0.82 (0.47 - 1.43)
Hematologic: Gynecological				0.38 (0.13 - 1.18)
Overall AUC	0.54	0.58	0.58	0.57

Table 4: Multilevel Poisson regression with outcome severe preeclampsia, bolding indicates statistical significance at 95% confidence

RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects
			RR (95% CI)	
(Intercept)	**0.45 (0.41 - 0.49)**	**0.23 (0.16 - 0.33)**	**0.23 (0.16 - 0.34)**	**0.23 (0.16 - 0.34)**
Race				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	**1.45 (1.29 - 1.63)**	**1.22 (1.06 - 1.41)**	1.15 (0.99 - 1.34)	1.16 (0.99 - 1.35)
Hispanic	1.09 (0.92 - 1.28)	1.04 (0.87 - 1.23)	0.97 (0.82 - 1.14)	0.97 (0.82 - 1.15)
Multiracial	**1.28 (1.02 - 1.60)**	1.09 (0.88 - 1.35)	1.06 (0.85 - 1.32)	1.06 (0.85 - 1.31)
Asian	0.93 (0.62 - 1.37)	0.98 (0.67 - 1.43)	0.96 (0.67 - 1.38)	0.97 (0.67 - 1.38)
Other	1.26 (0.81 - 1.96)	1.20 (0.78 - 1.86)	1.21 (0.76 - 1.91)	1.21 (0.77 - 1.91)
Confounders				
Pre-Pregnancy Conditions				
Cardiovascular			**1.77 (1.61 - 1.96)**	**1.71 (1.54 - 1.89)**
Kidney			**1.27 (1.03 - 1.56)**	**1.25 (1.01 - 1.53)**
Hematologic			0.90 (0.77 - 1.04)	0.80 (0.59 - 1.08)
Gastrointestinal			0.71 (0.48 - 1.05)	0.70 (0.47 - 1.05)
Gynecological			0.84 (0.70 - 1.02)	0.85 (0.71 - 1.02)
Combined effects				
Cardiovascular: Hematologic				1.26 (0.91 - 1.75)
Overall AUC	0.56	0.61	0.65	0.65


All Participants with Data on Pregnancy Outcomes
N = 9289
Excluded Pregnancy Outcomes (Fetal Demise, Elective Termination, Indicated Termination, Don't Know, Refused)
N = 360
N = 8929
Gestational Age (< 22) or (> 43)
N = 20
N = 8909
Labor, Delivery, and Postpartum (CMA) Form Not Completed
N = 144
N = 8765
Across Visits Conditions and Medications (VXX) Form Not Completed
N = 29
N = 8736
Race Missing
N = 3
N = 8733
Mode of Delivery Missing
N = 4
N = 8729